Focused On-demand Library for Fragile X messenger ribonucleoprotein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Fragile X messenger ribonucleoprotein; Protein FMR-1

Alternative UPACC:

Q06787; A6NNH4; D3DWT0; D3DWT1; D3DWT2; G8JL90; Q16578; Q5PQZ6; Q99054


Fragile X messenger ribonucleoprotein 1 (FMR1) plays a pivotal role in neuronal development and synaptic plasticity. It regulates mRNA splicing, stability, transport, and local protein synthesis at synapses. FMR1's involvement in liquid-liquid phase separation and its interaction with various mRNAs and proteins underscore its multifunctional nature. It binds preferentially to poly(G) RNA sequences, influencing pre- and postsynaptic functions.

Therapeutic significance:

FMR1 is linked to Fragile X syndrome, Fragile X tremor/ataxia syndrome, and Premature ovarian failure 1, diseases with profound neurodevelopmental and reproductive impacts. Understanding FMR1's mechanisms offers a pathway to targeted therapies, potentially reversing or mitigating symptoms associated with its dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.